Login or sign up
For business

BSIM Therapeutics

4.3· 12 reviews
Average ratingGreat
4.3/ 5

Based on 12 reviews

550%
425%
325%
20%
10%
Ask AI

Ask AI about BSIM Therapeutics

Generated with AI from 12 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About BSIM Therapeutics

BSIM’s mission is to deliver quality drug candidates with high capital efficiency against transthyretin-mediated amyloidosis, including clinical manifestations and related pathologies that represent important and unmet medical needs.

Our products are directed to a group of rare, hereditary and fatal pathologies commonly addressed to as Transthyretin Amyloidoses (hATTR). We are developing drug candidates that fit within distinct target-product profiles for the treatment of a broader range of hATTR manifestations, including central nervous system symptoms (e.g. seizures, stroke-like events, progressive dementia) and oculopathy (e.g. vitreous opacities, glaucoma).

Website
bsimtx.com